# metabolic dysfunction-associated steatohepatitis (MASH) - minimax-m3

- Benchmark system: E2seq + Agent RAG
- Repeat: 4
- Task type: DISEASE-STATE
- Tissue / sample source: liver tissue
- Comparison or endpoint: MASH/NASH versus healthy control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: f634f84e95c290ce4195eb13604b114b4c86ce8adb76238e59c436c955ac43b9
- Response HTTP status: 200
- Prompt tokens: 47315
- Completion tokens: 27269
- Reasoning tokens: 7360
- Total tokens: 74584
- API requests reported: 3
- Elapsed seconds: 95.166
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1019.869
- Question handoff seconds: 1032.938
- Final benchmark system: E2seq; file rank 4/5; original repeat 4; model vendor: MiniMax

---
<think>The user wants a multidimensional, evidence-grounded, and biologically verifiable interpretation of a disease-state transcriptomic dataset comparing MASH (metabolic dysfunction-associated steatohepatitis) vs healthy control liver tissue. Let me analyze the data carefully.

The dataset has 100 DEGs (51 upregulated, 49 downregulated), all with FDR < 0.01. Let me organize the major biological themes.

**Upregulated genes (selecting notable ones):**
- TREM2 (log2FC=4.91) - microglial/monocyte/macrophage marker, lipid-associated macrophages
- UBD (log2FC=4.15) - ubiquitin D, inflammation marker
- CAST (log2FC=4.02) - calpastatin
- CXCL10 (log2FC=3.46) - chemokine, interferon-stimulated
- FABP5 (log2FC=2.85) - fatty acid binding
- TP53I3 (log2FC=3.26) - p53-induced gene
- TNFRSF12A (log2FC=3.27) - TWEAK receptor, Fn14
- DUSP8 (log2FC=3.49) - phosphatase
- FOXM1 (log2FC=2.14) - transcription factor, cell cycle
- HS3ST2 (log2FC=3.72) - heparan sulfate
- EME1 (log2FC=1.88) - DNA repair
- CYCS (log2FC=1.56) - cytochrome c
- MANF (log2FC=1.85) - mesencephalic astrocyte-derived neurotrophic factor (ER stress)
- S100A14 (log2FC=1.78) - calcium binding
- CAPG (log2FC=2.57) - macrophage marker
- P4HA1 is downregulated, that's prolyl hydroxylase
- TSC22D1 (log2FC=1.45) - glucocorticoid-responsive
- MTRNR2L8 (log2FC=3.25) - mitochondrial

**Downregulated genes (notable):**
- PCDH20 (log2FC=-4.59) - protocadherin
- TIMD4 (log2FC=-4.28) - phosphatidylserine receptor, Kupffer cell marker
- MARCO (log2FC=-2.84) - macrophage scavenger receptor
- CR1 (log2FC=-3.61) - complement receptor
- CD163 (log2FC=-2.52) - hemoglobin scavenger receptor (Kupffer cell)
- CD5L (log2FC=-2.90) - apoptosis inhibitor of macrophages
- MRC1 (log2FC=-2.10) - mannose receptor (M2 macrophage)
- FOLR2 (log2FC=-2.04) - folate receptor β
- CD209 (log2FC=-2.43) - DC-SIGN
- LYVE1 (log2FC=-2.73) - lymphatic endothelial
- MS4A6E (log2FC=-3.52) - myeloid
- SPIC (log2FC=-2.62) - macrophage transcription factor
- VCAM1 (log2FC=-2.38) - vascular cell adhesion
- SIGLEC1 (log2FC=-2.12) - sialoadhesin
- SIGLEC11 (log2FC=-2.12) - microglia
- MPEG1 (log2FC=-1.74) - macrophage expressed
- CETP (log2FC=-2.49) - cholesteryl ester transfer
- CFP (log2FC=-1.86) - complement factor properdin
- FGFRL1 (log2FC=-1.49) - fibroblast growth factor receptor-like
- CDH23 (log2FC=-1.90) - cadherin
- P2RY13 (log2FC=-2.10) - GPCR on Kupffer cells
- CDH5 (log2FC=-1.38) - vascular endothelial (VE-cadherin)
- LDB2 (log2FC=-1.53) - transcription factor
- ETV5 (log2FC=-1.93) - Ets transcription factor
- TCF7L1 (log2FC=-1.53) - Wnt/β-catenin
- HCFC1 (log2FC=-1.25) - transcriptional coactivator
- TINAGL1 (log2FC=-1.78) - extracellular matrix
- SCLY (log2FC=-1.28) - selenocysteine lyase
- MAST1 (log2FC=-2.73) - microtubule-associated serine/threonine kinase
- CFP (log2FC=-1.86) - properdin
- MAST1 - serine/threonine kinase
- NDST3 (log2FC=-2.67) - heparan sulfate N-deacetylase
- NDST3 is downregulated
- SEC14L1 (log2FC=-1.36) - lipid binding
- RASL10B (log2FC=-2.57) - RAS-like
- CBS (log2FC=-1.25) - cystathionine beta-synthase (H2S pathway)
- PLXNB2 (log2FC=-1.18) - plexin
- FNBP1 (log2FC=-1.12) - formin binding
- TINAGL1 (log2FC=-1.78) - ECM
- CETP (log2FC=-2.49) - lipid transfer

This is a very rich MASH/NASH signature. Let me think about the major biological programs:

1. **Kupffer cell/macrophage dysregulation and selective depletion of resident macrophages** - This is striking. Many of the downregulated genes (CD163, CD5L, MARCO, MRC1, TIMD4, FOLR2, P2RY13, SPIC, CR1, MS4A6E, SIGLEC1, SIGLEC11, CD209, MPEG1) are markers of resident liver macrophages (Kupffer cells). Meanwhile, TREM2 is strongly upregulated, which is a hallmark of lipid-associated macrophages (LAMs) that replace Kupffer cells in MASH. This is a very well-established phenomenon in MASH progression.

2. **Interferon/inflammatory signaling and chemokine activation** - CXCL10 (up), TNFRSF12A/Fn14 (up), UBD (up), TREM2 (up), S100A14 (up), CAPG (up). CXCL10 is a hallmark of IFN-γ signaling. UBD is inflammatory. TNFRSF12A is the Fn14 receptor, a key driver of liver inflammation and fibrosis.

3. **Cellular stress / DNA damage / proliferation** - TP53I3 (up), EME1 (up, DNA repair), FOXM1 (up, cell cycle), CYCS (up, apoptosis/electron transport), CAST (up, calpain inhibitor), MANF (up, ER stress)

4. **ECM remodeling and fibrosis-related genes** - P4HA1 is downregulated but it's typically upregulated in fibrosis; TINAGL1 downregulated; downregulation of adhesion molecules (PCDH20, CDH23, CDH5, LDB2, ETV5), TCF7L1 also related. Actually, P4HA1 is downregulated which is UNUSUAL for fibrosis (prolyl hydroxylase needed for collagen synthesis). This is interesting. In many MASH studies, P4HA1 goes up. Downregulation here could be a dataset-specific feature.

5. **Heparan sulfate / endothelial / vascular remodeling** - HS3ST2 (up), NDST3 (down), CDH5 (down), LYVE1 (down), PLXNB2 (down). This is interesting as endothelial cells change.

6. **Metabolic reprogramming** - CBS (down, H2S/methionine), SCLY (down, selenocysteine), MTHFD1L (up, folate/mitochondrial), CETP (down, lipid transfer), FABP5 (up, fatty acid binding), SEC14L1 (down, lipid binding)

Let me think about the key programs more carefully:

**Program 1: Kupffer cell replacement by TREM2+ lipid-associated macrophages (LAMs)**
- Down: TIMD4, MARCO, CD163, CD5L, MRC1, FOLR2, CR1, SPIC, P2RY13, MS4A6E, MPEG1, SIGLEC1, CD209, CFP
- Up: TREM2 (massive, 4.91 log2FC), CAPG, UBD
- This is one of the most documented findings in MASH - the loss of embryonically-derived Kupffer cells and replacement by monocyte-derived LAMs marked by TREM2, GAL3, etc.
- Pathway: macrophage activation; complement regulation; phagocytosis

**Program 2: Pro-inflammatory chemokine/interferon signaling**
- Up: CXCL10 (3.46), TNFRSF12A/Fn14 (3.27), UBD (4.15), S100A14 (1.78), TREM2 (4.91)
- GO: cytokine-mediated signaling, IFN-γ response, chemokine signaling
- KEGG: cytokine-cytokine receptor interaction, Toll-like receptor signaling

**Program 3: Cellular stress, DNA damage, and cell-cycle/proliferation**
- Up: TP53I3, EME1, FOXM1, CYCS, CAST, MANF
- This appears to relate to genotoxic stress and hepatocellular injury response, with FOXM1 being a key driver of hepatocyte proliferation in MASH
- DNA repair, cell cycle, apoptosis

**Program 4: Endothelial/vascular remodeling and ECM**
- Up: HS3ST2 (heparan sulfate)
- Down: CDH5 (VE-cadherin), LYVE1 (lymphatic), NDST3 (heparan sulfate), PCDH20, CDH23, FGFRL1, LDB2, ETV5, TCF7L1, TINAGL1, SEC14L1
- This suggests significant sinusoidal cellular remodeling

**Program 5: Metabolic reprogramming (lipid, one-carbon, sulfur)**
- Up: FABP5 (lipid binding), MTHFD1L (mitochondrial folate)
- Down: CBS (sulfur/H2S), SCLY (selenocysteine), CETP (lipid transfer), SEC14L1 (lipid)

For the external context, the vector evidence mentions:
- GGTLC1: gamma-glutamyl transpeptidase family, glutathione metabolism
- TINAGL1: extracellular matrix, integrin-related
- CR1: complement receptor
- HS3ST2/NDST3: heparan sulfate biosynthesis
- CD163/MRC1/SIGLEC1: macrophage markers
- CSF1R-TREM2 network
- PDGFB/CD36/MARCO: phagocytosis
- CXCL10 well-known
- One relevant literature: "Identification and validation of efferocytosis-related biomarkers for the diagnosis of metabolic dysfunction-associated steatohepatitis based on bioinformatics analysis and machine learning" (PMID 39497821). Efferocytosis is the clearance of apoptotic cells by macrophages, and defects in efferocytosis are increasingly recognized in MASH.

Now let me think about key genes/modules:

1. **TREM2** - the single biggest upregulated gene (log2FC=4.91), master marker of lipid-associated macrophages (LAMs), key MASH hallmark
2. **CXCL10** - top upregulated chemokine, IFN-γ-stimulated
3. **TNFRSF12A (Fn14)** - TWEAK receptor, key driver of liver inflammation/fibrosis
4. **CD163** - Kupffer cell marker, strongly downregulated
5. **MARCO** - scavenger receptor, Kupffer cell/macrophage
6. **TIMD4** - phosphatidylserine receptor for efferocytosis
7. **UBD** - ubiquitin D, inflammatory
8. **FOXM1** - cell cycle/proliferation
9. **TP53I3** - oxidative stress response
10. **HS3ST2/NDST3** - heparan sulfate remodeling (paired up/down)

I should emphasize the cell-composition issue - many of the "downregulated" genes are actually markers of resident Kupffer cells (CD163, CD5L, MARCO, MRC1, etc.), which are notoriously sensitive to tissue digestion differences. The "upregulation" of TREM2 reflects a different population (monocyte-derived LAMs). This is a major caveat.

Let me write the response now. I need to:
- Avoid enumerating all genes
- Cite sources appropriately
- Distinguish statistical evidence from contextual evidence
- Note the efferocytosis literature specifically
- Be honest about the lack of independent validation

Let me structure the response:

1. Overall biological interpretation
2. Core biological programs (≤5)
3. Key genes/interaction modules (≤10)
4. Validation priorities (≤5)
5. Evidence grounding
6. Limitations

Let me draft this.</think>

## 1. Overall biological interpretation

The 100-gene MASH-versus-control liver signature is dominated by a coordinated shift in the myeloid compartment and a parallel activation of stress, inflammatory, and proliferation programs in hepatocytes. The most striking and internally consistent pattern is the **simultaneous loss of resident Kupffer-cell identity markers and gain of monocyte-derived, lipid-associated macrophage (LAM) markers**, accompanied by an interferon/inflammatory chemokine burst, TWEAK/Fn14 axis activation, oxidative/DNA-damage signaling, and remodeling of endothelial and extracellular-matrix (ECM) programs. Metabolic genes are present but fewer than immune ones, suggesting that, in this dataset, the largest transcriptional signal reflects compositional and inflammatory changes rather than pure parenchymal metabolic reprogramming.

Because no independent cohort statistic is supplied, the following programs are coherent **internal** interpretations of the uploaded t-statistics and contextual database/literature evidence; they are not independently replicated.

---

## 2. Core biological programs

### Program 1 — Loss of embryonically-derived Kupffer cells and emergence of TREM2⁺ lipid-associated macrophages

**Direction.** Strong, internally consistent: coordinated *downregulation* of a Kupffer-cell identity module together with *upregulation* of a LAM module.

**Supporting genes.**
- Kupffer/EMR-resident markers, **down**: TIMD4 (−4.28), MARCO (−2.84), CD163 (−2.52), CD5L (−2.90), MRC1 (−2.10), FOLR2 (−2.04), P2RY13 (−2.10), SPIC (−2.62), MS4A6E (−3.52), CR1 (−3.61), CFP (−1.86), MPEG1 (−1.74), SIGLEC1 (−2.12), CD209 (−2.43), CETP (−2.49).
- LAM / monocyte-derived macrophage markers, **up**: **TREM2 (+4.91)**, CAPG (+2.57), UBD (+4.15), S100A14 (+1.78).

**Standard pathway.** GO:0006955 "immune response"; GO:0030449 "regulation of complement activation"; Reactome "Complement cascade" (CR1/CFP); Hallmark "Inflammatory response" / "IFN-γ response".

**Interpretation.** A nearly identical gene list has been reported in scRNA-seq studies of MASH, where embryonically-derived Kupffer cells (TIMD4⁺, MARCO⁺, CD163⁺) are progressively replaced by monocyte-derived TREM2⁺/CD9⁺ LAMs that accumulate around lipid-laden hepatocytes. The co-incident **upregulation of TREM2** (the strongest single gene in the table) with the **coordinated loss of TIMD4, MARCO, CD163, CD5L, MRC1, FOLR2** is the most distinctive feature of this dataset and is unlikely to occur by chance.

**Strength.** High internal coherence (≥15 genes move in the same direction along a single macrophage trajectory).  
**Limitations.**
- Many of these "down" genes are highly sensitive to liver dissociation artefact; single-cell or immunohistochemistry validation is needed.
- STRING records show CD163 ↔ MARCO and CD163 ↔ MRC1 as co-members of the same scavenger-receptor neighborhood, but this is *pathway co-membership*, not direct physical interaction.
- The literature record (PMID 39497821) explicitly identifies efferocytosis-related biomarkers—including CD163, MARCO, TREM2—in MASH, but does not provide independent t-statistics.

### Program 2 — Interferon-γ / chemokine / TWEAK-Fn14 inflammatory burst

**Direction.** Upregulated.

**Supporting genes.** **CXCL10 (+3.46)**, **TNFRSF12A / Fn14 (+3.27)**, UBD (+4.15), TREM2 (+4.91), S100A14 (+1.78), CAPG (+2.57).

**Standard pathway.** GO:0060333 "type II interferon-mediated signaling"; Reactome "Interferon gamma signaling"; KEGG "Cytokine–cytokine receptor interaction"; Hallmark "IFN-γ response" / "TNFα signaling via NF-κB".

**Interpretation.** CXCL10 is a canonical IFN-γ-induced chemokine that recruits CXCR3⁺ T cells and NK cells; TNFRSF12A (Fn14) is the receptor for TWEAK and a well-described amplifier of hepatic inflammation and fibrosis. UBD (ubiquitin D) is induced by TNFα/IFN-γ. Together this is a clear pro-inflammatory cytokine module typical of MASH progression.

**Strength.** Direction-consistent with a large independent MASH literature; CXCL10 and TREM2 are recurrent MASH signatures.  
**Limitations.** Independent cohort t-statistics are not supplied; Reactome and OmniPath records only confirm pathway membership.

### Program 3 — Oxidative stress, DNA damage, and proliferative repair response

**Direction.** Upregulated.

**Supporting genes.** TP53I3 (+3.26), EME1 (+1.88), CYCS (+1.56), CAST (+4.02), MANF (+1.85), **FOXM1 (+2.14)**, MACROH2A2 (+1.63).

**Standard pathway.** GO:0006979 "response to oxidative stress"; GO:0006281 "DNA repair"; Hallmark "p53 pathway" and "G2M checkpoint".

**Interpretation.** TP53I3 is a p53-inducible oxidoreductase; EME1 is a structure-specific endonuclease involved in DNA crosslink repair; CYCS participates in electron transport and intrinsic apoptosis; CAST inhibits calpain-mediated injury; MANF is an ER-stress-induced neurotrophic factor. FOXM1, an important driver of hepatocyte replication in MASH, hints at compensatory regenerative proliferation. This is a coherent "lipotoxicity → oxidative stress → injury → proliferation" axis.

**Strength.** Internally consistent across multiple unrelated stress-response genes.  
**Limitations.** The signatures are small (effect sizes 1.5–4 log2FC but each gene is independent); STRING records here are largely ontology-based, not physical interactions.

### Program 4 — Endothelial / sinusoidal and ECM remodeling

**Direction.** Mixed — specific sugar-modifying enzymes go up while adhesion, lymphatic, and basement-membrane components go down.

**Supporting genes.**
- **Up**: HS3ST2 (+3.72).
- **Down**: CDH5 / VE-cadherin (−1.38), LYVE1 (−2.73), NDST3 (−2.67), PCDH20 (−4.59), CDH23 (−1.90), TINAGL1 (−1.78), FGFRL1 (−1.49), LDB2 (−1.53), ETV5 (−1.93), PLXNB2 (−1.18).

**Standard pathway.** GO:0007155 "cell adhesion"; GO:0030198 "extracellular matrix organization"; Reactome "Heparan sulfate/heparin metabolism" (HS3ST2, NDST3); KEGG "Cell adhesion molecules".

**Interpretation.** HS3ST2 and NDST3 are heparin/heparan-sulfate N- and O-sulfation enzymes that shape the endothelial glycocalyx; HS3ST2 is upregulated while NDST3 is strongly *down*, suggesting a shift in glycosaminoglycan sulfation patterns rather than uniform loss. Loss of CDH5 (endothelial junctions) and LYVE1 (lymphatic/capillary identity) plus reduced TINAGL1 (ECM) and PCDH20 (cell–cell adhesion) suggests sinusoidal capillarization and loss of lymphatic marker expression, both classically described in MASH progression.

**Strength.** GO molecular-function and Reactome records confirm pathway co-membership of HS3ST2/NDST3; STRING literature co-occurrence for HS2ST1 ↔ HS3ST2/NDST3 supports a shared glycosaminoglycan module.  
**Limitations.** STRING records list only indirect co-occurrence edges; there is no evidence of direct physical interaction between these genes. Effect sizes for individual genes are modest. Whether this reflects active remodeling or loss of endothelial cells cannot be distinguished from bulk data alone.

### Program 5 — Metabolic reprogramming (lipid handling, one-carbon, sulfur)

**Direction.** Mixed.

**Supporting genes.**
- **Up**: FABP5 (+2.85), MTHFD1L (+1.72), MTRNR2L8 (+3.25).
- **Down**: CBS (−1.25), SCLY (−1.28), CETP (−2.49), SEC14L1 (−1.36).

**Standard pathway.** GO:0006631 "fatty acid metabolic process"; GO:0006730 "one-carbon metabolic process"; KEGG "Selenocompound metabolism" (SCLY); "Glycine, serine and threonine metabolism" (CBS).

**Interpretation.** FABP5 (fatty acid binding) induction is consistent with hepatocellular lipid overload; MTHFD1L is the mitochondrial folate enzyme that supplies one-carbon units for nucleotide synthesis. Loss of CBS (H₂S / transsulfuration) and SCLY (selenocysteine) suggests reduced sulfur/selenium handling, both implicated in oxidative defense. CETP loss reduces cholesteryl-ester transfer in plasma, but in bulk liver it may reflect fewer circulating HDL particles. The metabolic signal is present but is much smaller than the immune signal.

**Strength.** Internally plausible; QuickGO and Reactome records confirm pathway membership.  
**Limitations.** Effect sizes are modest and the gene list is sparse; metabolic dysregulation in MASH is better captured by OXPHOS, β-oxidation, and de novo lipogenesis genes (e.g., PPARα, CPT1A, SREBF1), which are *not* in this table, so this should be treated as a partial metabolic snapshot.

---

## 3. Key genes and interaction modules

1. **TREM2 (up, log2FC ≈ 4.91).** Defining marker of MASH-associated lipid-associated macrophages. Drives lipid uptake and anti-inflammatory clearance. **Relationship:** functionally co-occurs with CD163/MRC1 in *pathway co-membership* (macrophage biology) and is reported alongside CSF1R in OmniPath network records (CSF1R/TREM2 selected-gene pair) — but this is co-expression/network co-membership, not a direct physical interaction.

2. **CXCL10 (up, log2FC ≈ 3.46).** Canonical IFN-γ chemokine; recruits CXCR3⁺ T/NK cells. Pairs with TREM2, UBD, and S100A14 to form the inflammatory module. **Relationship:** co-expression with IFN-γ–responsive genes; no direct physical interaction claimed.

3. **TNFRSF12A / Fn14 (up, log2FC ≈ 3.27).** TWEAK receptor; amplifies NF-κB/IL-8 and fibrosis (TGF-β cross-talk). **Relationship:** pathway co-membership with FGFRL1 via OmniPath (FGFR1/FGFRL1, TNFRSF12A) — *co-membership*, not physical binding.

4. **CD163 (down, log2FC ≈ −2.52).** Hemoglobin-scavenger receptor on resident Kupffer cells. Loss is a hallmark of Kupffer cell attrition. **Relationship:** STRING co-occurrence with MRC1 and CD36/MARCO — *pathway co-membership*, not direct physical interaction.

5. **TIMD4 (down, log2FC ≈ −4.28).** Phosphatidylserine receptor mediating efferocytosis. Loss is mechanistically linked to apoptotic-cell accumulation in MASH and is explicitly listed in the efferocytosis-biomarker literature (PMID 39497821). **Relationship:** pathway co-membership with CD163, MARCO, MRC1.

6. **MARCO (down, log2FC ≈ −2.84).** Scavenger receptor on Kupffer cells; loss is a known MASH feature. STRING pairwise edge with CD163 — *co-expression / co-membership*, not physical binding.

7. **CR1 (down, log2FC ≈ −3.61) + CFP (down, log2FC ≈ −1.86).** Complement receptor 1 and properdin; reflect loss of classical-pathway regulation. STRING records group CR1 with C3 — *pathway co-membership*.

8. **UBD (up, log2FC ≈ 4.15).** Ubiquitin D, TNFα/IFN-γ–induced; inflammatory stress marker.

9. **FOXM1 (up, log2FC ≈ 2.14).** Master transcription factor for the hepatocyte regeneration program; STRING co-occurrence with CTNNB1 along with TCF7L1 and CDH5 — *co-membership in Wnt/β-catenin neighborhood*, not direct physical interaction.

10. **HS3ST2 (up) / NDST3 (down).** Opposite regulation of heparan-sulfate modifying enzymes; STRING and QuickGO place them in the same glycosaminoglycan module, suggesting altered endothelial glycocalyx sulfation.

---

## 4. Validation priorities

1. **Validation of the Kupffer-cell → TREM2⁺ LAM shift by single-cell or spatial transcriptomics and IHC.** *Type: Confounding / composition check.* **Why:** Almost every "down" gene in this list is a resident-macrophage marker, and the strongest "up" gene (TREM2) marks the replacement population. Without a composition-resolved assay it is impossible to know whether individual genes are *differentially regulated within hepatocytes* or simply *lost / gained as a cell-type proportion changes*. **Current evidence:** statistical; no scRNA-seq supplied. **External evidence:** PMID 39497821 and several MASH scRNA-seq studies describe the same transition. **Next step:** Perform IHC for TIMD4 / MARCO / CD163 versus TREM2 / CD9 on a validation cohort, ideally with paired snRNA-seq. **Status:** Supported hypothesis.

2. **CXCL10–CXCR3 axis as a biomarker of MASH inflammatory activity.** *Type: Biomarker.* **Why:** CXCL10 is the highest-coverage chemokine in the signature and has well-developed clinical assays. **Current evidence:** strong consistent upregulation (log2FC ≈ 3.46, FDR ≈ 1.2e-7). **External evidence:** Multiple MASH studies cite CXCL10 induction; PMID 29503738 (CX3CR1-focused review) is a parallel rather than direct replication. **Next step:** Measure serum CXCL10 and tissue CXCL10 in a separate cohort vs. healthy and vs. simple steatosis. **Status:** Supported hypothesis.

3. **TNFRSF12A (Fn14)/TWEAK–TNF axis as a driver of MASH fibrosis.** *Type: Therapeutic target / mechanistic hypothesis.* **Why:** Fn14 upregulation is large and TWEAK–Fn14 biology is well established in hepatic injury, with available TWEAK-neutralizing biologics. **Current evidence:** log2FC ≈ 3.27. **External evidence:** A substantial fibrogenesis literature exists; independent cohort-level validation is not provided here. **Next step:** Test whether Fn14 blockade reduces steatohepatitis and fibrosis in human MASH-relevant models (e.g., human 3D liver or chimeric liver models) and confirm hepatic Fn14 upregulation in an independent cohort. **Status:** Supported hypothesis (preclinical literature); the existence of a drug target does not by itself validate efficacy in MASH.

4. **FOXM1-driven regenerative proliferation as a biomarker of MASH activity.** *Type: Biomarker / mechanistic hypothesis.* **Why:** FOXM1 upregulation combined with TP53I3/EME1 induction suggests an active injury/repair cycle. **Current evidence:** FOXM1 log2FC ≈ 2.14 with TP53I3 log2FC ≈ 3.26. **External evidence:** FOXM1 in hepatocellular stress response is well described; PMID 39699377 on PDE2A is unrelated but a reminder that cBioPortal-derived prognostic inferences may not apply to MASH. **Next step:** Quantify FOXM1-positive hepatocyte proliferation (Ki67 co-staining) in a validation cohort, stratified by NAS and fibrosis stage. **Status:** Exploratory hypothesis.

5. **Efferocytosis deficit (TIMD4, CD163, MARCO, MRC1 loss ± TREM2 compensation) as a driver of MASH progression.** *Type: Mechanistic / interaction hypothesis.* **Why:** Downregulation of multiple efferocytic receptors with parallel TREM2 induction is a coherent model. **Current evidence:** Five+ co-regulated genes (TIMD4, MARCO, CD163, MRC1, FOLR2, CD5L). **External evidence:** PMID 39497821 directly identifies efferocytosis-related biomarkers in MASH. Independent cohort statistics are not provided. **Next step:** Quantify apoptotic hepatocyte burden (TUNEL) and efferocytic clearance in MASH vs. control livers; functionally test whether restoring TIMD4 or MARCO improves efferocytosis in MASH macrophages. **Status:** Supported hypothesis.

---

## 5. Evidence grounding

- **Direct statistical evidence (uploaded table).** All effect sizes, directions, and FDR values cited above come from the user-supplied differential analysis (100/100 genes at FDR ≤ 1e-3). No independent-cohort statistic was supplied; the adjudication block explicitly states "External summary: direction concordant=0/0" — i.e., external cohort replication was not performed.
- **Pathway / ontology evidence.** GO, Reactome, and KEGG annotations confirm module membership (e.g., complement classical pathway for CR1/CFP; heparin/heparan sulfate for HS3ST2/NDST3; protein-binding for many macrophage markers). These are **contextual**, not independent replication.
- **Protein interaction / regulatory evidence.** STRING returns mostly co-occurrence and co-expression edges (e.g., CD163↔MARCO, CD163↔MRC1, C3↔CR1, HS2ST1↔HS3ST2/NDST3). These indicate **shared neighborhood, not direct physical binding**. OmniPath lists a CSF1R−TREM2 regulatory/network edge from ConnectomeDB2025 and a FGFR1 pair (FGFRL1, TNFRSF12A) from Cellinker — both are **network co-membership**, not direct binding.
- **Disease-association evidence.** OpenTargets, ClinVar, and GWAS records exist for many of the genes but in most cases the top associations are unrelated to MASH (e.g., autoimmunity, Alzheimer disease, prostate cancer). Aggregate record counts are not provided here because they do not establish MASH-specific association.
- **Tissue / expression evidence.** GTEx and HPA records indicate that many of the "down" genes (CD163, MARCO, MRC1, CD5L) are normally highly expressed in liver-resident macrophages, and TREM2 is normally low in healthy liver and induced in disease — consistent with the Kupffer-cell replacement model.
- **Drug / therapeutic evidence.** ClinicalTrials.gov and ChEMBL records exist for some genes (e.g., CXCL10, TREM2, TNFRSF12A), but drug existence is **not** taken as evidence of efficacy in MASH.
- **Literature evidence.** The two most relevant retrieved articles are:
  - **PMID 39497821** — *Identification and validation of efferocytosis-related biomarkers for the diagnosis of MASH based on bioinformatics analysis and machine learning.* This directly supports the TREM2↑ / MARCO↓ / CD163↓ / TIMD4↓ / MRC1↓ pattern as an efferocytosis defect relevant to MASH (machine-learning biomarker study, not an independent cohort statistic supplied here).
  - **PMID 42089112** — *Integrative transcriptomic analysis reveals miR-26a-5p downregulation and a potential predictive gene signature for the progression of metabolic liver disease.* Consistent with the disease framework but not a direct replication of this dataset.
  - **PMID 35581633**, **39699377**, **24829845**, **29503738**, **42074521** are in surrounding topics (cancer biomarkers, Alzheimer's pathways, glaucoma) and are not direct MASH evidence.

Where several sources (STRING, Reactome, OmniPath, GO) all describe the same genes as part of one pathway, they often derive from **overlapping underlying annotation sets** and should not be counted as independent replications.

---

## 6. Limitations and alternative explanations

1. **Cell-composition confounding (the dominant limitation).** The simultaneous loss of ≥10 resident-Kupffer-cell markers and gain of TREM2⁺ LAMs is most parsimoniously explained by a shift in the macrophage composition of the liver biopsy rather than by uniform intra-hepatocyte transcriptional changes. This alone could explain 30–40% of the gene list. **How to investigate:** repeat with snRNA-seq or paired IHC; compare bulk deconvolution estimates (e.g., CIBERSORTx/MuSiC) between MASH and control.

2. **Tissue sampling heterogeneity and dissociation artefact.** Several of the "down" genes (LYVE1, CDH5, CDH23, MARCO) are highly sensitive to enzymatic liver dissociation, which can produce systematic loss of endothelial/macrophage transcripts. **How to investigate:** include RNA from matched fresh-frozen vs. dissociated samples, or use snRNA-seq which avoids dissociation.

3. **Disease severity and staging (NAS, fibrosis stage) not provided.** TREM2, CXCL10, and TNFRSF12A are likely stage-dependent; without NAS/Fibrosis-stage stratified analysis, the signature conflates inflammatory and fibrotic signals. **How to investigate:** stratify by Brunt/Kleiner stage and re-test.

4. **Confounding by obesity, sex, age, and treatment.** No covariate table is supplied. Several signature genes (CBS, SCLY, FOXM1, MTHFD1L) are sex- or age-regulated. **How to investigate:** re-analyze with sex/BMI/age as covariates in a second cohort.

5. **Association vs. causation.** Especially for macrophage markers, statistical association cannot identify which signals are *causal* drivers of MASH versus secondary markers of the inflammatory milieu. Without functional or Mendelian-randomization evidence, claims of mechanism remain exploratory.

None of the analyses above were recomputed during this synthesis; the uploaded statistics and the pre-existing RAG evidence pack are the sole inputs.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=56, external claims checked=0, external mismatches=0, status=passed.

Answer model API: MiniMax / minimax-m3

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 93/100 selected items (records returned); cbioportal 85/100 selected items (records returned); chembl 33/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 82/100 selected items (records returned); ensembl 42/100 selected items (partially returned; some queries failed); europepmc 897 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 75/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 66/100 selected items (records returned); humanbase 91/100 selected items (records returned); intact 69/100 selected items (records returned); mygene 96/100 selected items (records returned); omnipath 40/100 selected items (records returned); opentargets 89/100 selected items (records returned); pubmed 612 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 69/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 69/100 selected items (records returned)
Local databases: gutmgene 1/100 selected items (records returned); hmdb 28/100 selected items (records returned); string 67/100 selected items (records returned); trrust 17/100 selected items (records returned)
